Even though, our data suggest that CIS patients that show high CXCL13 concentrations in CSF and fulfill Barkhof criteria in MRI are at high risk to develop MS and should therefore be candidates for an early treatment with an immunomodulatory therapy. Here, CXCL13 is linked to in situ carcinoma.